Please login to the form below
Olumiant
This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).
Latest news
-
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
tofacitinib) and Eli Lilly’s Olumiant (baricitinib). ... The revised report also determined that Xeljanz had a comparable net health benefit to Humira, while there is no evidence to compare Olumiant to the older treatment.
-
Second TULIP trial resurrects AZ’s lupus drug anifrolumab
There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)
-
AbbVie scores FDA approval for arthritis treatment upadacitinib
The JAK inhibitor market competition has also become increasingly saturated and upadacitinib will be taking on Pfizer’s Xeljanz and Eli Lilly’s Olumiant when it comes to market.
-
Gilead and Galapagos close in on filing for Xeljanz rival
If approved, filgotinib would likely be the fourth JAK inhibitor for RA after Pfizer’s $1.8bn seller Xeljanz (tofacitinib), Eli Lilly’s Olumiant (baricitinib), and AbbVie’s upadacitinib which has ... In both studies there was a low incidence of
-
New data keeps AbbVie’s star pipeline therapies on track
Lilly reported positive phase II results with its already-approved Olumiant (baricitinib) drug in the skin disorder at last year’s EADV, as did Pfizer with PF-04965842, a more selective
More from news
Approximately 5 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Consultant
-
competitive salary
-
Vice President
-
Competitive Salary Offered
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- Pfizer signs $507m cancer deal with Effector Therapeutics
- Key success factor (KSF)
- How do companies prepare for reimbursement?
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
PMHub
OUTiCO
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...
Latest intelligence
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
Quick links
Infographics
